Physician profile
Salman Saeed
NPI 1528051125
$21,781.84
in general payments reported to CMS, 2019-2025
60 companies · $3,471 in 2025
The $3,471 reported for 2025 was more than what 81% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,132 · 2020: $2,130 · 2021: $3,799 · 2022: $3,512 · 2023: $3,592 · 2024: $3,147 · 2025: $3,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $83.51 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,102.61 |
| Education | $83.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,408.16 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,461.51 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,387.68 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Biogen, INC. | $1,243.37 | 2019-2025 | Vumerity, Tysabri |
| Sk Life Science, INC. | $1,175.91 | 2020-2025 | |
| Emd Serono, INC. | $1,063.77 | 2019-2025 | Mavenclad |
| Lilly USA, LLC | $982.48 | 2019-2025 | Emgality, Kisunla |
| Ucb, INC. | $964.65 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Neurocrine Biosciences, INC. | $773.83 | 2020-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $735.67 | 2019-2025 | Vyepti |
| Pfizer INC. | $718.98 | 2021-2025 | |
| Argenx US, INC. | $676.17 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amneal Pharmaceuticals LLC | $660.01 | 2019-2025 | Rytary, Crexont, Ongentys |
| Mdd US Operations, LLC | $567.95 | 2019-2025 | Gocovri, Myobloc, Apokyn |
| Sunovion Pharmaceuticals INC. | $555.63 | 2019-2022 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.